All In Biotech

Drug Trial Radar · NCT05091346

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

89

Actual

Start

Oct 27, 2021

Primary completion

Oct 15, 2024

Study completion Oct 15, 2024

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembrolizumab. The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab (melanoma, colorectal cancer \[CRC\], hepatocellular carcinoma \[HCC\]) or of E7386 in combination with pembrolizumab plus lenvatinib (HCC) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

Conditions

  • Melanoma
  • Carcinoma, Hepatocellular
  • Colorectal Neoplasms

Interventions

  • E7386Drug

    E7386 tablet.

  • PembrolizumabDrug

    Pembrolizumab IV infusion.

  • LenvatinibDrug

    Lenvatinib capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (Cycle length=21 days)
  2. Phase 1b Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 30 days after last dose of study drug (up to 12.73 months)
  3. Phase 1b Part: Number of Participants With Serious TEAEsTime frame: Up to 90 days after last dose of study drug (up to 14.73 months)
  4. Phase 2 Part: Objective Response Rate (ORR)Time frame: Up to 20.40 months

Locations

32 sites in 4 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

  • University of California, Irvine Health

    Orange, California

  • Florida Cancer Specialists

    Fort Myers, Florida

  • SCRI Florida Cancer Specialists East

    West Palm Beach, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Barbara Ann Karmanos Cancer Center

    Detroit, Michigan

  • Rutgers cancer Institute of NJ

    New Brunswick, New Jersey

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Providence Medical Center Institute Franz Clinic

    Portland, Oregon

  • Tennessee Oncology PPLC

    Nashville, Tennessee

  • Chiba University Hospital

    Chiba, Japan

  • National Cancer Center Hospital

    Chūōku, Japan

  • Kurume University Hospital

    Fukuoka, Japan

  • National Cancer Center Hospital East

    Kashiwa, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Kindai University Hospital

    Ōsaka-sayama, Japan

  • Sapporo-Kosei General Hospital

    Sapporo, Japan

  • Shizuoka Cancer Center Hospital

    Shizouka, Japan

  • Toranomon Hospital

    Tokyo, Japan

  • Hospital Universitario de Badajoz

    Badajoz, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • Hospital Universitario de la Paz

    Madrid, Spain

  • Consorcio Hospital General Universitario de Valencia

    Valencia, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, Avenida Carolos Haya S/n, Spain

  • Hospital Clínico San Carlos

    Madrid, Calle Profesor Martín Lagos, Spain

  • Clínica Universidad de Navarra

    Pamplona, Navarre, Spain

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Imperial College London - Hammersmith Hospital

    London, United Kingdom

  • Royal Free Hospital NHS Foundation Trust

    London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.